Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer	HR+/HER2- Advanced Breast Cancer; Targeted Therapy	Recruiting	Phase 2	2023-08-09		NCT05983107

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	294

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing	China	10

Clinical trials